Outcome of long term active surveillance for estrogen receptor-positive ductal carcinoma in situ

Breast

Volumn 20, Issue 6, 2011, Pages 529-533

  Meyerson, Anna F ^a,b   Lessing, Juan N ^a   Itakura, Kaoru ^a   Hylton, Nola M ^a   Wolverton, Dulcy E ^a,c   Joe, Bonnie N ^a   Esserman, Laura J ^a   Hwang, E Shelley ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Quantum Radiology   (United States)

^c Radiology Imaging Associates   (United States)

Author keywords

Breast MRI; DCIS; ER positive; Non surgical management; Surveillance

Indexed keywords

ANASTROZOLE; ESTROGEN RECEPTOR; LETROZOLE; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST BIOPSY; CANCER CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER INVASION; CANCER RISK; CANCER STAGING; CANCER SURGERY; CONTROLLED STUDY; DISEASE DURATION; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN TISSUE; INTRADUCTAL CARCINOMA; LONG TERM CARE; MAJOR CLINICAL STUDY; MASTECTOMY; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PARTIAL MASTECTOMY; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

EID: 82955248044     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2011.06.001     Document Type: Article

References (24)

1. Ernster V.L., Ballard-Barbash R., Barlow W.E., Zheng Y., Weaver D.L., Cutter G., et al. Detection of ductal carcinoma in situ in women undergoing screening mammography. J Natl Cancer Inst 2002 Oct 16, 94(20):1546-1554.
2. Burstein H.J., Polyak K., Wong J.S., Lester S.C., Kaelin C.M. Ductal carcinoma in situ of the breast. N Engl J Med 2004 Apr 1, 350(14):1430-1441.
3. Virnig B.A., Tuttle T.M., Shamliyan T., Kane R.L. Ductal carcinoma in situ of the breast: a systematic review of incidence, treatment, and outcomes. J Natl Cancer Inst 2010 Feb 3, 102(3):170-178.
4. Kuhl C.K., Schrading S., Bieling H.B., Wardelmann E., Leutner C.C., Koenig R., et al. MRI for diagnosis of pure ductal carcinoma in situ: a prospective observational study. Lancet 2007 Aug 11, 370(9586):485-492.
5. Hwang E.S., Kinkel K., Esserman L.J., Lu Y., Weidner N., Hylton N.M. Magnetic resonance imaging in patients diagnosed with ductal carcinoma-in-situ: value in the diagnosis of residual disease, occult invasion, and multicentricity. Ann Surg Oncol 2003 May, 10(4):381-388.
6. Marcotte-Bloch C., Balu-Maestro C., Chamorey E., Ettore F., Raoust I., Flipo B., et al. MRI for the size assessment of pure ductal carcinoma in situ (DCIS): a prospective study of 33 patients. Eur J Radiol 2009 Nov 5.
7. Jansen S.A., Paunesku T., Fan X., Woloschak G.E., Vogt S., Conzen S.D., et al. Ductal carcinoma in situ: X-ray fluorescence microscopy and dynamic contrast-enhanced MR imaging reveals gadolinium uptake within neoplastic mammary ducts in a murine model. Radiology 2009 Nov, 253(2):399-406.
8. Hwang E.S., Esserman L. Neoadjuvant hormonal therapy for ductal carcinoma in situ: trial design and preliminary results. Ann Surg Oncol 2004 Jan, 11(1 Suppl):37S-43S.
9. Li C.I., Daling J.R., Malone K.E. Age-specific incidence rates of in situ breast carcinomas by histologic type, 1980 to 2001. Cancer Epidemiol Biomarkers Prev 2005 Apr, 14(4):1008-1011.
10. Allegra C.J., Aberle D.R., Ganschow P., Hahn S.M., Lee C.N., Millon-Underwood S., et al. National institutes of health State-of-the-science conference statement: diagnosis and management of ductal carcinoma. J Natl Cancer Inst 2009, 102(3):161-169. In Situ September 22-24, Feb 3.
11. Sanders M.E., Schuyler P.A., Dupont W.D., Page D.L. The natural history of low-grade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long-term follow-up. Cancer 2005 Jun 15, 103(12):2481-2484.
12. Collins L.C., Tamimi R.M., Baer H.J., Connolly J.L., Colditz G.A., Schnitt S.J. Outcome of patients with ductal carcinoma in situ untreated after diagnostic biopsy: results from the nurses' health study. Cancer 2005 May 1, 103(9):1778-1784.
13. Eusebi V., Feudale E., Foschini M.P., Micheli A., Conti A., Riva C., et al. Long-term follow-up of in situ carcinoma of the breast. Semin Diagn Pathol 1994 Aug, 11(3):223-235.
14. Leach M.O., Boggis C.R., Dixon A.K., Easton D.F., Eeles R.A., Evans D.G., et al. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet 2005 May 21-27, 365(9473):1769-1778.
15. Dent R., Warner E. Screening for hereditary breast cancer. Semin Oncol 2007 Oct, 34(5):392-400.
16. Kuhl C.K., Schrading S., Leutner C.C., Morakkabati-Spitz N., Wardelmann E., Fimmers R., et al. Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. J Clin Oncol 2005 Nov 20, 23(33):8469-8476.
17. Causer P.A., Jong R.A., Warner E., Hill K., Wong J.W., Curpen B.N., et al. Breast cancers detected with imaging screening in the BRCA population: emphasis on MR imaging with histopathologic correlation. Radiographics 2007 Oct, 27(Suppl. 1):S165-S182.
18. Fisher B., Costantino J.P., Wickerham D.L., Redmond C.K., Kavanah M., Cronin W.M., et al. Tamoxifen for prevention of breast cancer: report of the National surgical adjuvant breast and bowel project P-1 study. J Natl Cancer Inst 1998 Sep 16, 90(18):1371-1388.
19. Fisher B., Dignam J., Bryant J., DeCillis A., Wickerham D.L., Wolmark N., et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 1996 Nov 6, 88(21):1529-1542.
20. Fisher B., Costantino J.P., Wickerham D.L., Cecchini R.S., Cronin W.M., Robidoux A., et al. Tamoxifen for the prevention of breast cancer: current status of the National surgical adjuvant breast and bowel project P-1 study. J Natl Cancer Inst 2005 Nov 16, 97(22):1652-1662.
21. Fisher B., Dignam J., Wolmark N., Wickerham D.L., Fisher E.R., Mamounas E., et al. Tamoxifen in treatment of intraductal breast cancer: National surgical adjuvant breast and bowel project B-24 randomised controlled trial. Lancet 1999 Jun 12, 353(9169):1993-2000.
22. Allred D.C.B.J., Land S., Paik S., Fisher E., Julian T., Margolese R.S.R., et al. Estrogen receptor expression as a predictive marker of the effectiveness of tamoxifen in the treatment of DCIS: findings from NSABP protocol B-24. Breast Cancer Res Treat 2002, 76(Suppl. 1):S36. [Abstract]. 2002.
23. Hoff P.M., Valero V., Buzdar A.U., Singletary S.E., Theriault R.L., Booser D., et al. Combined modality treatment of locally advanced breast carcinoma in elderly patients or patients with severe comorbid conditions using tamoxifen as the primary therapy. Cancer 2000 May 1, 88(9):2054-2060.
24. Chen Y.Y., DeVries S., Anderson J., Lessing J., Swain R., Chin K., et al. Pathologic and biologic response to preoperative endocrine therapy in patients with ER-positive ductal carcinoma in situ. BMC Cancer 2009, 9:285.